Seth M. Birnbaum joins the board of directors of pharmaceutical company Hallux Inc.

“We are delighted to have Seth join Hallux as a member of the Board of Directors. The Board of Directors is both personally invested in Hallux and extremely experienced in pharmaceutical development and specifically in onychomycosis.” ~Mark Taylor, CEO of Hallux Inc.

Hallux Inc, a clinical-stage pharmaceutical company, today announced that following the initial closing last month of its $9.4 million Series A-2 funding round, Seth M. Birnbaum, seasoned partner of Bridgewater Associates, was appointed to its board of directors. Proceeds from the capital increase will be used to further fund the Company’s Phase 2 clinical program evaluating Hallux Subungual Gel (HSG) for the treatment of onychomycosis (nail fungus).

Hallux CEO Mark Taylor said, “On behalf of our entire Board of Directors, we are delighted to have Seth join Hallux as a Director. Our board members are both personally invested in Hallux and extremely experienced in clinical development, particularly in onychomycosis. Seth’s skills and deep experience in capital formation and value creation are two critical disciplines the company needs as we pursue our mission to provide patients around the world with a highly effective topical medicine to cure this infection often difficult to treat.

Seth M. Birnbaum, CFA is a 20-year veteran at Bridgewater Associates, where he is a partner and senior member of the investment team. His expertise includes economic market and investment analysis, risk management, and portfolio strategy and design. In 2019, Seth was named to the Institutional Investors Hedge Fund Rising Stars list. Seth graduated magna cum laude from Amherst College with a BA in Economics, Philosophy and Political Science, with honors. He is a board member of Open Doors.

About Hallux

Hallux Inc. is a clinical-stage pharmaceutical company focused on developing a new dosage form and route of administration for the treatment of onychomycosis (nail fungus). Hallux’s goal is to provide high efficacy and safety to patients with chronic onychomycosis worldwide. The Company’s experimental approach with its novel terbinafine HSG-based topical subungual drug candidate is to demonstrate safety and high efficacy through direct and selective delivery to the site of bedside infection. of the nail.

Share the article on social networks or by e-mail:

Comments are closed.